SMARCA2 and cancer: This has significant implications for small-molecule drug discovery as SMARCA2 knock-down causes cancer-specific, phenotypic lethality in SMARAC4-null lung cancers [31–33], but bromodomain inhibition does not phenocopy the effects of RNAi-mediated target depletion [35].